ATE367160T1 - Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma - Google Patents

Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma

Info

Publication number
ATE367160T1
ATE367160T1 AT02787795T AT02787795T ATE367160T1 AT E367160 T1 ATE367160 T1 AT E367160T1 AT 02787795 T AT02787795 T AT 02787795T AT 02787795 T AT02787795 T AT 02787795T AT E367160 T1 ATE367160 T1 AT E367160T1
Authority
AT
Austria
Prior art keywords
ccr
asthma
treatment
receptor antagonists
piperazine derivatives
Prior art date
Application number
AT02787795T
Other languages
English (en)
Inventor
Bois Daisy Du
Denis Kertesz
Eric Sjogren
David Smith
Beihan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE367160T1 publication Critical patent/ATE367160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
AT02787795T 2001-11-30 2002-11-25 Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma ATE367160T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33465501P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
ATE367160T1 true ATE367160T1 (de) 2007-08-15

Family

ID=23308174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787795T ATE367160T1 (de) 2001-11-30 2002-11-25 Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma

Country Status (16)

Country Link
US (1) US6906073B2 (de)
EP (1) EP1453514B1 (de)
JP (1) JP2005516903A (de)
KR (1) KR100586131B1 (de)
CN (1) CN1321115C (de)
AR (1) AR037459A1 (de)
AT (1) ATE367160T1 (de)
AU (1) AU2002352122A1 (de)
BR (1) BR0214582A (de)
CA (1) CA2467966A1 (de)
DE (1) DE60221275T2 (de)
ES (1) ES2290346T3 (de)
MX (1) MXPA04004981A (de)
PL (1) PL370746A1 (de)
RU (1) RU2004120063A (de)
WO (1) WO2003045393A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087685A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
US7262197B2 (en) * 2003-03-31 2007-08-28 Janssen Pharmaceutica, N.V Phospholipase C inhibitors for use in treating inflammatory disorders
EP1640361B9 (de) * 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetrische harnstoff-verbindungen und verfahren zur herstellung von asymmetrischen verbindungen durch asymmetrische konjugat-additionsreaktion unter verwendung dieser verbindungen als katalysator
JP2007537275A (ja) * 2004-05-12 2007-12-20 ケモセントリックス， インコーポレイテッド アリールスルホンアミド
WO2007005214A1 (en) * 2005-06-29 2007-01-11 Janssen Pharmaceutica, N.V. Substituted {4(4-phenyl-piperazin-1yl)-cyclohexyl}-urea compounds
US8183239B2 (en) * 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
WO2009006185A1 (en) * 2007-07-03 2009-01-08 Janssen Pharmaceutica, N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
JP2012501344A (ja) * 2008-08-29 2012-01-19 トレヴェンティス コーポレイション アミロイド症を治療する組成物及び方法
CN102459210B (zh) * 2009-04-22 2015-09-02 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
KR101687144B1 (ko) * 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
CN110520127B (zh) 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
EP3821947A1 (de) * 2019-11-13 2021-05-19 Libra Therapeutics, Inc. Heterozyklische agonisten von trpml1
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592921A (ja) 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
DE69829875T2 (de) * 1997-10-14 2006-03-09 Mitsubishi Pharma Corp. Piperazin-verbindungen und ihre medizinische verwendung
JP2002179651A (ja) * 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd ベンズアニリド誘導体及び医薬組成物
HK1044282A1 (zh) 1998-12-18 2002-10-18 Bristol-Myers Squibb Pharma Company 作为趋化因子受体活性调节剂的n-脲基烷基-哌啶化合物
AU2057200A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2347909A1 (en) 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
AR037459A1 (es) 2004-11-10
MXPA04004981A (es) 2004-08-11
EP1453514A1 (de) 2004-09-08
DE60221275T2 (de) 2008-05-08
CN1321115C (zh) 2007-06-13
DE60221275D1 (de) 2007-08-30
CN1599611A (zh) 2005-03-23
US6906073B2 (en) 2005-06-14
RU2004120063A (ru) 2005-06-10
US20030176441A1 (en) 2003-09-18
WO2003045393A1 (en) 2003-06-05
AU2002352122A1 (en) 2003-06-10
ES2290346T3 (es) 2008-02-16
JP2005516903A (ja) 2005-06-09
EP1453514B1 (de) 2007-07-18
PL370746A1 (en) 2005-05-30
CA2467966A1 (en) 2003-06-05
BR0214582A (pt) 2004-11-03
KR20040065570A (ko) 2004-07-22
KR100586131B1 (ko) 2006-06-07

Similar Documents

Publication Publication Date Title
DE60221569D1 (de) Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE50014041D1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE371451T1 (de) Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
NO20033417L (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties